Astec LifeSciences Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 507.95 million compared to INR 1,171.81 million a year ago. Revenue was INR 517.04 million compared to INR 1,209.7 million a year ago. Net loss was INR 243.34 million compared to net income of INR 8.4 million a year ago. Basic loss per share from continuing operations was INR 12.41 compared to basic earnings per share from continuing operations of INR 0.43 a year ago. Diluted loss per share from continuing operations was INR 12.41 compared to diluted earnings per share from continuing operations of INR 0.43 a year ago.
For the nine months, sales was INR 3,044.32 million compared to INR 5,011.94 million a year ago. Revenue was INR 3,080.29 million compared to INR 5,116.79 million a year ago. Net loss was INR 459.56 million compared to net income of INR 305.48 million a year ago. Basic loss per share from continuing operations was INR 23.44 compared to basic earnings per share from continuing operations of INR 15.58 a year ago. Diluted loss per share from continuing operations was INR 23.44 compared to diluted earnings per share from continuing operations of INR 15.58 a year ago.